chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. Information regarding relevant medical history and concurrent condition were not reported. On 04-NOV-2015 the patient was vaccinated with oral, ROTATEQ (lot # L008057, expiration date 01-DEC-2016, dose not reported), which was exposed to temperatures outside of the recommended temperature (incorrect product storage). No adverse experience had been reported. This is one of several reports received from the same source. Additional information has been requested.
9PM Headache. 10PM, HA escalated, pt profusely diaphoretic (changed shirt & pants X3, nausea. Symptoms slowly subsided by 12:30. 36 hrs after injection, developed a 4 inch x 1.5 inch raised white area at injection site - with pruritis. Lasted four days.
numbness in hands, joints, knees & feet almost collapsed;2min p/shot feet milldly numb;10min later more numb;began to breathe heaily;nausea & SOB lasted 2 1/2hr;eyes were heavy & felt panic;tingling;metallic taste in mouth;
I am experiencing a lingering metallic taste in my mouth and wonder if it is related to the vaccine.
Information has been received from a nurse practitioner concerning a pt who was vaccinated with Varicella virus vaccine live more than a year ago, approximately in 1997.  The nurse practitioner reported that the pt developed shingles. She stated that the  injection site was the arm and the herpes zoster has developed on the left side of the body, not the arm and does not cross midline". Unspecified medical attention was sought. Additional information has been sought.
not feeling completely normal; general weakness; injection site is sore to touch; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (not feeling completely normal), ASTHENIA (general weakness) and VACCINATION SITE PAIN (injection site is sore to touch) in an 88-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Jan-2021, the patient experienced FEELING ABNORMAL (not feeling completely normal), ASTHENIA (general weakness) and VACCINATION SITE PAIN (injection site is sore to touch). At the time of the report, FEELING ABNORMAL (not feeling completely normal), ASTHENIA (general weakness) and VACCINATION SITE PAIN (injection site is sore to touch) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The patient's medical history was not provided. Concomitant medications was not reported.  This case concerns a 88 year old male subject with, who experienced the unlisted events of feeling abnormal and asthenia. The events occurred 1 day  after first dose of IP. No action was taken with IP. The event´s outcome were unknown on 16 Apr 2021. The events were considered possible related to IP in agreement with the reporter due to temporal association.   Reporter did not allow further contact; Sender's Comments: This case concerns a 88 year old male subject with, who experienced the unlisted events of feeling abnormal and asthenia. The events occurred 1 day  after first dose of IP. No action was taken with IP. The event´s outcome were unknown on 16 Apr 2021. The events were considered possible related to IP in agreement with the reporter due to temporal association.
Large area raised rash at injection site; Injection site swelling; Tenderness around the injection site; Redness all around injection site; This spontaneous case was reported by a health care professional (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE ERYTHEMA (Redness all around injection site) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (Redness all around injection site). At the time of the report, VACCINATION SITE ERYTHEMA (Redness all around injection site) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported. No treatment information was provided.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded
I did not have any reaction with the first one other than headache; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 72-year-old female patient received bnt162b2 (BNT162B2) (Lot number: EN6200) at the age of 72 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Blood pressure" (unspecified if ongoing), notes: Verbatim: Blood pressure; "Thyroid" (unspecified if ongoing), notes: Verbatim: Thyroid. Concomitant medication(s) included: LEVOTHYROXINE taken for thyroid disorder; ALOPINE taken for blood pressure abnormal. The following information was reported: HEADACHE (non-serious), outcome "unknown", described as "I did not have any reaction with the first one other than headache".  Additional information: Patient did not have any reaction with the first one other than headache.  No follow-up attempts are possible. No further information is expected.
fast heartrate around 115 BMP as if she was running; Triggered/exaggerated her asthma; shivering; she was very cold; fever of 104 F; massive headache like her head was being split open; extreme massive chills; swelling arm; Feel warm; Felt dizzy; felt very fatigue and sleepy; This spontaneous case was reported by a physician and describes the occurrence of HEART RATE INCREASED (fast heartrate around 115 BMP as if she was running), FEELING COLD (she was very cold) and ASTHMA (Triggered/exaggerated her asthma) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026L20A and 012M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included ZINC SULFATE (LIQUID ZINC), B-vitamin Complex, ASCORBIC ACID, ROSA CANINA FRUIT (VITAMIN C & ROSEHIP), CALCIUM CARBONATE, COLECALCIFEROL (VITAMIN D 2000), MULTIVITAMIN & MINERAL, MENAQUINONE-7 (VITAMIN K 2), SELENIUM, PROBIOTIC 10, LEVOTHYROXINE SODIUM (SYNTHROID), Albuterol inhaler and nebulizer and Symbicort                                                      BID for an unknown indication.   On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 11-Feb-2021, the patient experienced HEART RATE INCREASED (fast heartrate around 115 BMP as if she was running), FEELING COLD (she was very cold) and ASTHMA (Triggered/exaggerated her asthma). On 11-Feb-2021, ASTHMA (Triggered/exaggerated her asthma) had resolved. At the time of the report, HEART RATE INCREASED (fast heartrate around 115 BMP as if she was running) and FEELING COLD (she was very cold) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
mild reaction at the site of injection; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site reaction in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 21-JUL-2023, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site reaction (Verbatim: mild reaction at the site of injection). The outcome of the injection site reaction was unknown.   It was unknown if the reporter considered the injection site reaction to be related to Shingrix.     It was unknown if the company considered the injection site reaction to be related to Shingrix.   Additional Information: GSK Receipt date: 02-AUG-2023 The reporter reported about herself she had her first Shingrix vaccination on 21 July 2023 and experienced mild reaction at the site of injection. No further information was known. For tolerance refer case US2023105234, reported by same reporter The reporter did not consent to follow up.; Sender's Comments:  US-GSK-US2023105234:Same reporter
Within 5 mins. of vaccine, became lightheaded, weak, chills and shaky.  Was sent home. Called to say he made it home.   2/25/22 called to check on him; he was better, just some intermittent fevers.   2/28/22 his wife called wanting to know what to do as he has not been out of bed since Friday night, having fevers, unable to stand.  Advised to call ambulance but unable to reach them since 1:15 p.m.  today.
[Johnson and Johnson Covid 19 vaccine ] treatment under Emergency Use Authorization(EUA): Patient received JJ vaccine on 4/8/21. Vaccine was given about 1.5 cm below the acromion process per doctor measurement. Patient noticed a small lump at injection site within 15 minutes. That night patient had 'pins and needles' down her left arm, arm/hand tremors, chills/fever (102.3), nausea, body aches, fatigue and shoulder pain. Patient took ibuprofen at 4am 4/9. Saturday (4/10) patient noticed a lump on her left forearm. Patient had an ultrasound done (4/14) on her left arm and a supraficial, venous thrombosis in the cephalic vein of the left forearm was found. Patient was told to start aspirin 81mg on 4/15.  venous thrombosis in cephalic vein of left forearm found
This spontaneous report was received from a certified medical assistant and refers to an unspecified number of patients of unknown age and gender. Information on the patients' concurrent conditions, medical history or concomitant medications was not reported. On an unknown date, the patients were vaccinated with improperly stored doses of GARDASIL (lot # L020162, expiration date: 23-JUL-2017), dose and route were not provided. No adverse symptoms reported. This is one of two reports received from the same source. Additional information has been requested.
Information has been received from a registered pharmacist concerning a female patient who on an unspecified date was vaccinated with a dose of ZOSTAVAX (Merck). On an unspecified date the patient experienced an injection site bruise. At the time of report the patient's status was unknown. Additional information has been requested. This is one of several reports from the same source.
Night sweats, chills, fever, searing headache, muscle aches, fatigue, grogginess. All symptoms began approximately eight hours after injection and lasted throughout the night into the next day and subsided at approximately noon. Tylenol was used to subdue symptoms on the second day.
still ill after the double dose flu shot; ill; Initial information was received on 16-Jan-2021 regarding an unsolicited valid serious case received from a consumer  This case involved adult male patient who was still ill after the double dose flu shot (illness) and ill (malaise), while he received INFLUENZA VACCINE.  The patient's medical history, medical treatment(s), vaccination(s), concomitant medication (s) and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number and expiration date not reported via unknown route at unknown administration site for prophylactic vaccination.  On an unknown date, the patient was still ill after the double dose flu shot (illness) and ill (malaise), unknown latency following the administration of INFLUENZA VACCINE.   The patient was hospitalized (caused or prolonged) for this event.  No relevant laboratory data was reported.   It was not reported if the patient received a corrective treatment.  The event outcome was reported as unknown for both the events.  There will be no information available on the batch number for this case.; Sender's Comments: This case concerns adult male patient who was still ill after the double dose flu shot and ill after vaccination with INFLUENZA VACCINE. It was unknown if the time to onset was compatible. However, concomitant medications,  patient's medical condition and laboratory tests ruling out alternate etiologies. Moreover, vaccination preceded the events. Based upon the reported information, the role of vaccine cannot be assessed.
First injection's adverts effects, Temp VAERS E-report number  339683.  **REACTIONS TO 2ND VACCINE:  (I opted to stay for observation for an hour, in case an EpiPen was needed. I have no prior history of anaphylaxis. I hadn't heard from moderna or CDC prior to 2nd shot, so felt it was best to err on the side of caution)  *oral numbness beginning 5 minutes after shot  *full oral numbness, and back of throat numbness, by 10min. Full numbness like with novocain injections.  *felt suddenly faint at about 10 minutes post vaccine, subsided at about 30 minutes post vaccine.  *lips tingling by 8 minutes post vaccine.  *lips numb by 10 minutes.  *facial tingling (cheeks and nose) about 15 minutes.  *numb cheeks and nose by about 20 minutes post vaccine.   *facial numbness lasted about 18 hours, oral numbness lasted almost 36 hours. Similar to the first shot but more intense and came on faster.   *arm soreness and injection site redness has not subsided 4 days out. Starting day 3 in the evening, the redness is spreading and feels like deep bruising. This seems to be in line with delayed cutaneous hypersensitivity, in my non-professional opinion. Day 4 it has spread further. Pictures are attached, if they help for documentation reasons.   *most other side effects experienced are well documented to be expected: these side effects were more intense than shot #1- nausea, diarrhea, fever (100.2), chills, aches, fatigue, headache, arm pain and redness, etc. I do feel that my immune system response going wonky has triggered a vaginal yeast infection post vaccine (only ever experienced this 2 other times in my life, also when my immune system took a hit).
This spontaneous report was received from a physician and refers to a patient of unknown age (also reported as "0") and gender. No information about the patient's pertinent medical history, concomitant medications and concurrent conditions was provided. On 26-APR-2017, the patient was vaccinated with an improperly stored dose of  ROTATEQ oral solution, lot # M041181 (dose, and expiry date were not specified) for prophylaxis. The administered dose of ROTATEQ underwent a temperature excursion of 48 Fahrenheit degrees for 30 minutes. There was no Digital Data Logger involved. No previous temperature excursion was reported. No adverse effects were reported. Product quality complaint (PQC) was not involved. This is one of several reports received from the same reporter. Additional information is not expected as all available information has been received.; Sender's Comments:  US-009507513-1704USA000587: US-009507513-1704USA001660: US-009507513-1704USA001661:
1 1/2 hrs with vaccine Rt arm felt tight and tender. Worse in evening red, swollen and more tender all below shot site. Fever on 1/16/07 100.6. Treated with Septra DS, Zyrtec, and ice. Almost completely resolved by 1/19/07.
Client stated she got TD in 1986. Left arm swollen and injection site swollen since Friday. Swollen went down since Friday. Client stated she took Goody body pain medication from Friday until today at 16:00.
has not been feeling well; low blood pressure; feeling very cold; clammy; This is a spontaneous report from contactable consumer. This contactable female consumer (Patient) reported for herself. A 52-years-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date as SINGLE DOSE for COVID-19 immunisation. The patient medical history was not reported. Concomitant medication included metoprolol (METOPROLOL) taken for hypotension, start and stop date were not reported. On an unspecified date She received the first dose on Monday at 07:00PM and had not been feeling well. Patient had been experiencing low blood pressure and feeling very cold and clammy. Patient did not take her heart medication (Metoprolol) because of the low blood pressure. The patient went to the ER but she says they didn't know what to do.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Within 3 hours of vaccine administration she felt inflammation at site of injection. By the next morning, inflammation with heat and firmness in area covered an 18 X 15cm oval area of L upper outer arm with some tenderness at site of edema, slight tenderness.
second dose was the Pfizer Covid19 Vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (second dose was the Pfizer Covid19 Vaccine) in a 22-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.    Concurrent medical conditions included Cancer.   On 30-Aug-2021, the patient received second dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (Intramuscular) 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Aug-2021, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (second dose was the Pfizer Covid19 Vaccine). On 30-Aug-2021, INTERCHANGE OF VACCINE PRODUCTS (second dose was the Pfizer Covid19 Vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient wanted to know if she need to get a booster of Moderna or Pfizer in the future. She didn't remember her concomitant medications. No Treatment medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 31-Aug-2021: Follow-up information received on 31-AUG-2021 contains non-significant information
Patient had pain which got better, but the site of injection then started to itch and became red. She also stated that it is warm to the touch and there is swelling. Over the next couple of days it did spread on her upper arm.
25OCT 1230PM vax recvd & 27OCT 1030PM few hives on rt back (upper), 1130PM itchy, more hives on body; 28OCT 7AM hives all over body & upper thighs & very itchy; 10AM seen by MD given med;
Difficulty breathing, severe tingling in hands and feet, spike in heart rate and blood pressure, closing throat, itching and hives, heart palpitations and taste of vaccine after injection and nausea.
This spontaneous report as received from a pharmacist refers to a patient of unknown gender and age. The patient's medical history and concurrent conditions were not reported. On 04-FEB-2015, the patient was vaccinated with an expired dose of PNEUMOVAX 23 lot # J005067, expiration date: 17-JAN-2015, intramuscular injection (dose and dose number were not provided). Information about concomitant therapy was not provided. No known adverse effects were reported. No product quality complaint (PQC) was involved. Additional information has been requested.
APPROXIMATELY 1717, PATIENT WENT UNRESPONSIVE IN OBSERVATION. PATIENT RESPONDED TO VERBAL AND PHYSICAL STIMULI, MOVED TO COT. @ 1719, VSS - BP 96/68, P 70, R 24, O2 98% RA. ICE PACK, SNACK, AND WATER PROVIDED. PER MOM, "HE HAS AN ARRYTHMIA PROBLEM, WHEN THIS HAPPENS HE NEEDS SALT." PATENT ENCOURAGED TO REST AND FINISH THE CHIPS PROVIDED BY OBSERVATION STAFF.  PATIENT REASSESED BY NP @ 1732. VITAL SIGNS REMAIN STABLE. BP 100/70, P 70, R 18, O2 98% RA. PATIENT REPORTED "I FEEL BETTER NOW." MOM EDUCATED TO NOTIFY STAFF AT NEXT DOSE APPOINTMENT TO REQUEST COT FOR VACCINATION AND ENSURE PATIENT EATS AND DRINKS WATER PRIOR TO VACCINE.
Local redness at injection site swelling, pain, mild cellulitis vaccine given on 9/20/2011 & symptoms started 9/21/2011.
patient developed flu like symptoms such as body aches, chills, fever,  as well as arm pain day after vaccination.
Swollen injection site Multiple blood clots Right radial arterial fully ecluded Forearm pain
7/7/21 hx of A-fib on Eliquis, CHF, COPD that presents as a lvl 1 trauma after fall
Patient is reporting arm pain that starts from the neck to the palm of the hand and indicates that it feels like it's constantly moving through her arm. These started two weeks after getting the COVID-19 MODERNA vaccine. Also she has swelling in her hands, and indicates that the pain improves with Diclofenac and Baclofen, but does not go away.
I developed an initial fever of 101.2° and was completely bed bound, then that same initial day I began to develop extremely painful and unexplainable mouth sores and lesions. Some developed on my cheeks, some developed on my tongue and they were so painful that I could not eat, drink water, or even talk. I continued to spike fevers for an entire week without being able to control it. The pain was so unbearable and nothing was helping the pain go away, I am still unable to eat solid foods although I no longer have fevers. My throat also really hurt and my neck lymph nodes felt sore to the touch. The lesions in my mouth are beginning to heal but I am still bed bound and am trying to recover. Only thing I can bring myself to eat is chicken broth. I saw multiple doctors, not one of them was able to figure out the source of these awful lesions. They put me on acyclovir and cefuroximeacetil as an antibiotic.
This case was reported by a healthcare professional and described the occurrence of vertigo in a 61-year-old male subject who was vaccinated with FLUARIX (GlaxoSmithKline). The subject's medical history included vertigo. On 19 September 2012 the subject received 1st dose of FLUARIX (.5 unknown, unknown, left deltoid). On 20 September 2012, 1 day after vaccination with FLUARIX, the subject experienced vertigo. An employee health nurse reported that a nurse, who received the flu vaccine annually, received FLUARIX on 19 September 2012 and experienced vertigo on 20 September 2012. The vertigo resolved for about two to three days but then returned again. The physician at employee health did not believe the FLUARIX was related to the vertigo, so she referred him to his primary care physician. The subject previously experienced vertigo in January 2012, not related to a vaccination. At the time of reporting the vertigo was unresolved. The healthcare professional considered the event was unrelated to vaccination with FLUARIX.
Narrative:  COVID INFECTION following completion of COVID vaccine series and prior infection 11/17 COVID positive 02/22 COVID vaccine dose #1 03/15 COVID vaccine dose #2 05/10 symptoms started: coughing dry heaves, chest wall aches from coughing so much 05/12 presented for COVID testing due to 2 day h/o sore throat and myalgia, cough, resolution of chest wall ache